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Objective: European healthcare systems are under constant pressure to contain healthcare 
expenditure. Understanding future drug expenditure is an important consideration for payers when 
formulating policies. QuintileIMS publishes European forecasts that are underpinned by its audited 
volume data and publicly available list prices. With increasing price pressures, list to net price 
divergence is growing, although some of this information is commercially sensitive and thus not 
publicly available. The objective of this study was to further develop an established forecast to account 
for this divergence and explore its impact. 
 
Methods: QuintilesIMS forecast of pharmaceutical expenditure in EU5 countries through 2021 is 
developed based on its capture of medicines pack data and using previously described methodologies 
(QuintilesIMS Market Prognosis publications). The top-line forecast was adjusted for each country to 
account for rebates and discounts that are not reflected within QuintilesIMS data, including industry-
level rebates and product-level discounts to national, regional and hospital payers. Average 
rebate/discounts levels were estimated from aggregate data reported by national health system 
organisations, industry associations and interviews with country experts. Sensitivity analysis was 
undertaken to address uncertainty around estimates. 
 
Results: The QuintilesIMS forecast based on list prices predicts average compound annual growth 
rates (CAGR) of 3% across EU5. Using OECD data to account for rebates and discounts reduces the 
predicted expenditure growth rate by 1 to 2% points. Ongoing analyses are in development to explore 
extent and variation of this reduction across countries. 
 
Conclusion: The increasing frequency and magnitude of patient access schemes, rebates and 
discounts have led to a growing divergence between list and net prices for medicines in Europe. This 
is driven by policies such as external reference pricing, growth in risk sharing arrangements and a shift 
in pharmaceutical innovation from retail to hospital settings. Adjusting for these discounts is important 
to understand the future real pharmaceutical expenditure growth in Europe. 
